[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Aloysius MM, Zaitoun AM, Bates TE, Ilyas M, Constantin-Teodosiu D, Rowlands BJ, Lobo DN: Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer? BMC Cancer; 2010;10:80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: a potential target for drug therapy of periampullary cancer?
  • METHODS: This was a retrospective study on tissue microarrays constructed from formalin-fixed paraffin-embedded tissue from 126 consecutive patients (cancer = 104, chronic pancreatitis = 22) undergoing pancreatic resections between June 2001 and June 2006.
  • 78 specimens of chronic pancreatitis tissue were obtained adjacent to areas of cancer.
  • Normal pancreatic tissue was obtained from the resection specimens in a total of 30 patients.
  • RESULTS: MMCs I, III, IV and V were highly expressed (p < 0.05) in all primary periampullary cancers compared with metastatic lymph nodes and adjacent benign pancreas.
  • MMCs III, IV and V were highly expressed in all cancers regardless of type compared with chronic pancreatitis (p < 0.05).
  • CONCLUSIONS: Differential expression of MMCs III, IV and V in primary periampullary cancers compared with adjacent benign periampullary tissue and chronic pancreatitis is a novel finding, which may render them attractive anticancer targets.
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Epithelium / drug effects. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Oxidative Stress. Pancreas / pathology. Pancreatitis / pathology. Phosphorylation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Aug 18;289(5482):1150-1 [10970229.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jul;68(1):9-19 [11678313.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Nov 1;176(3):145-52 [11714246.001]
  • [Cites] Cell. 2003 Feb 21;112(4):481-90 [12600312.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L189-98 [12665464.001]
  • [Cites] Trends Mol Med. 2004 Aug;10(8):372-8 [15310457.001]
  • [Cites] BMJ. 2004 Sep 18;329(7467):668-73 [15374918.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3641-7 [8252480.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Mar 11;328(2):623-32 [15694394.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1606-25 [15887154.001]
  • [Cites] Biochem Pharmacol. 2005 Jul 1;70(1):1-12 [15907809.001]
  • [Cites] Cell Metab. 2005 Jun;1(6):401-8 [16054089.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4787-97 [16892091.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4812-30 [16892093.001]
  • [Cites] Exp Physiol. 2006 Sep;91(5):807-19 [16857720.001]
  • [Cites] FEBS Lett. 2006 Oct 2;580(22):5125-9 [16979626.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Mar 2;354(1):50-5 [17214968.001]
  • [Cites] J Bioenerg Biomembr. 2007 Feb;39(1):65-72 [17294131.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jul;293(1):C12-21 [17475665.001]
  • [Cites] Gut. 2007 Aug;56(8):1134-52 [17625148.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 7;364(1):131-7 [17931597.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1593-600 [19223492.001]
  • [Cites] BMC Cancer. 2009;9:327 [19754967.001]
  • [Cites] Oral Oncol. 2001 Jan;37(1):72-6 [11120486.001]
  • (PMID = 20202214.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2841142
  •  go-up   go-down


2. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK: Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res; 2001 Mar;7(3):524-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
  • In this report, we present data indicating that the increased serum endoglin (EDG; CD105) quantitated by a double-antibody sandwich assay is associated with metastasis in patients with solid tumors including colorectal and breast carcinomas.
  • In addition, we show that chemotherapy exerts a suppressive effect on the serum EDG.
  • We generated two anti-EDG monoclonal antibodies (mAbs), termed SN6a and SN6h, defining different epitopes of EDG and developed a double-antibody sandwich assay to quantitate serum EDG in patients with solid tumors.
  • We measured serum samples from 101 patients with solid tumors (34 colorectal cancers, 16 breast cancers, and 51 other cancers), 8 patients with benign diseases, and 31 healthy volunteers.
  • Of the breast cancer patients, the difference in EDG levels between the 11 metastasis-positive patients and the normal control was statistically significant (P < 0.005).
  • In additional studies, we found that chemotherapy suppressed serum EDG levels in cancer patients.
  • Of the 54 metastasis-positive patients with solid tumors, the mean serum EDG in the 32 chemotherapy-receiving [chemotherapy(+)] patients was 44.7 +/- 41.9 ng/ml (median value, 36.1 ng/ml), whereas the value in the 22 chemotherapy(-) patients was 102.4 +/- 99.5 ng/ml (median value, 64.8 ng/ml).
  • In the majority of metastasis-positive patients who were not receiving chemotherapy, serum EDG was elevated.
  • The results suggest that serum EDG may be a useful marker for monitoring early signs of metastasis and cancer relapse in a long-term follow-up of solid tumor patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / blood. Breast Neoplasms / pathology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Neoplasm Metastasis. Vascular Cell Adhesion Molecule-1 / blood
  • [MeSH-minor] Animals. Antibodies, Monoclonal / metabolism. Antibody Affinity. Antigens, CD. Binding, Competitive. Biomarkers, Tumor. Cell Division. Dose-Response Relationship, Immunologic. Electrophoresis, Polyacrylamide Gel. Epitopes / metabolism. Female. Humans. Immunohistochemistry. Kinetics. Male. Mice. Mice, Inbred BALB C. Neovascularization, Pathologic. Precipitin Tests. Radioimmunoassay. Receptors, Cell Surface. Recurrence

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11297243.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Epitopes; 0 / Receptors, Cell Surface; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


3. Warrenfeltz S, Pavlik S, Datta S, Kraemer ET, Benigno B, McDonald JF: Gene expression profiling of epithelial ovarian tumours correlated with malignant potential. Mol Cancer; 2004 Oct 7;3:27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improved knowledge of gene expression changes and functional pathways associated with these clinical phenotypes may lead to new treatment targets, markers for early detection and a better understanding of disease progression.
  • RESULTS: Gene expression profiling (Affymetrix, U95Av2) was carried out on 18 ovarian tumours including benign adenomas, borderline adenocarcinomas of low malignant potential and malignant adenocarcinomas.
  • Clustering the expression profiles of samples from patients not treated with chemotherapy prior to surgery effectively classified 92% of samples into their proper histopathological group.
  • Some cancer samples from patients treated with chemotherapy prior to surgery clustered with the benign adenomas.
  • Chemotherapy patients whose tumours exhibited benign-like expression patterns remained disease free for the duration of this study as indicated by continued normal serum CA-125 levels.
  • CONCLUSION: Our findings indicate that gene expression profiling can reliably distinguish between benign and malignant ovarian tumours.
  • Expression profiles of samples from patients pre-treated with chemotherapy may be useful in predicting disease free survival and the likelihood of recurrence.
  • Expression levels in borderline tumours were intermediate between benign adenomas and malignant adenocarcinomas for a significant portion of the differentially expressed genes, suggesting that borderline tumours are a transitional state between benign and malignant tumours.
  • [MeSH-minor] Cluster Analysis. Epithelial Cells / pathology. Female. Gene Expression Profiling. Humans. Multigene Family. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:155-63 [15153430.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4722-9 [12183431.001]
  • [Cites] Curr Urol Rep. 2004 Jun;5(3):157-65 [15161563.001]
  • [Cites] Biochim Biophys Acta. 2004 Jun 7;1654(2):105-22 [15172699.001]
  • [Cites] Mol Cancer. 2004 Apr 26;3:12 [15109395.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):255-67 [9516080.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2907-12 [10077610.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):686-92 [14760385.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1796-806 [15014034.001]
  • [Cites] Eur J Haematol. 2004 May;72(5):307-13 [15059064.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):5-9 [15128001.001]
  • [Cites] Oncogene. 2002 Sep 12;21(41):6289-98 [12214269.001]
  • [Cites] Int J Cancer. 2002 Oct 20;101(6):549-54 [12237896.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):499-512 [12413931.001]
  • [Cites] Oncology. 2002;63(4):317-32 [12417786.001]
  • [Cites] J Cell Physiol. 2003 Feb;194(2):108-16 [12494449.001]
  • [Cites] Curr Opin Obstet Gynecol. 2003 Feb;15(1):39-43 [12544500.001]
  • [Cites] Mol Carcinog. 2003 Feb;36(2):53-9 [12557260.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Genomics. 2003 Feb;81(2):98-104 [12620386.001]
  • [Cites] Curr Opin Cell Biol. 2003 Apr;15(2):213-20 [12648678.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1449-53 [12670888.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:71-83 [12724213.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Mol Cell Endocrinol. 2003 Apr 28;202(1-2):89-96 [12770736.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):172-7 [12800191.001]
  • [Cites] Semin Oncol. 2003 Jun;30(3):401-12 [12870142.001]
  • [Cites] Adv Exp Med Biol. 2003;532:39-49 [12908548.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Genome Res. 2003 Oct;13(10):2291-305 [12975311.001]
  • [Cites] Mol Biol Cell. 2003 Nov;14(11):4376-86 [12960427.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] J Soc Gynecol Investig. 2004 Jan;11(1):51-9 [14706684.001]
  • [Cites] Leukemia. 2004 Feb;18(2):233-7 [14628069.001]
  • [Cites] Virchows Arch. 2000 May;436(5):403-12 [10881733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81 [11158614.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):539-51 [11469685.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Cancer Treat Res. 2002;107:99-118 [11775463.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Am J Epidemiol. 2002 Jul 15;156(2):148-57 [12117706.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2387-95 [15160342.001]
  • (PMID = 15471544.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC524500
  •  go-up   go-down


Advertisement
4. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res; 2007 Jan 1;13(1):90-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
  • PURPOSE: The distribution and significance of caveolin 1 (CAV1) expression in different breast cell types and role in breast carcinogenesis remain poorly understood.
  • Both tumor-suppressive and oncogenic roles have been proposed for this protein.
  • The aims of this study were to characterize the distribution of CAV1 in normal breast, benign breast lesions, breast cancer precursors, and metaplastic breast carcinomas; to assess the prognostic significance of CAV1 expression in invasive breast carcinomas; and to define whether CAV1 gene amplification is the underlying genetic mechanism driving CAV1 overexpression in breast carcinomas.
  • EXPERIMENTAL DESIGN: CAV1 distribution in frozen and paraffin-embedded whole tissue sections of normal breast was evaluated using immunohistochemistry, immunofluorescence, and immunoelectron microscopy.
  • CAV1 expression was immunohistochemically analyzed in benign lesions, breast cancer precursors, and metaplastic breast carcinomas and in a cohort of 245 invasive breast carcinomas from patients treated with surgery followed by anthracycline-based chemotherapy.
  • RESULTS: In normal breast, CAV1 was expressed in myoepithelial cells, endothelial cells, and a subset of fibroblasts.
  • CAV1 was expressed in 90% of 39 metaplastic breast carcinomas and in 9.4% of 245 invasive breast cancers.
  • CONCLUSIONS: The concurrent CAV1 amplification and overexpression call into question its tumor-suppressive effects in basal-like breast carcinomas.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / ultrastructure. Carcinoma / pathology. Carcinoma / ultrastructure. Caveolin 1 / biosynthesis. Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods. In Situ Hybridization
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunophenotyping. Microscopy, Fluorescence. Microscopy, Immunoelectron. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200343.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


5. Parreira LM, Sípoli JM, Mercante AM, Orfali RL, Levites J: Case for diagnosis: (unilateral multiple piloleiomyoma). An Bras Dermatol; 2009 Mar-Apr;84(2):197-9
Hazardous Substances Data Bank. HYDROXYZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case for diagnosis: (unilateral multiple piloleiomyoma).
  • Piloleiomyoma is a benign neoplasm arising from the erector pilorum muscle in the skin.
  • [MeSH-minor] Antipruritics / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Female. Humans. Hydroxyzine / administration & dosage. Muscle, Smooth / pathology. Pain / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19503991.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antipruritics; 30S50YM8OG / Hydroxyzine
  •  go-up   go-down


6. Parker SJ, Harries SA: Phyllodes tumours. Postgrad Med J; 2001 Jul;77(909):428-35
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phyllodes tumours are rare fibroepithelial lesions that account for less than 1% of all breast neoplasms.
  • With the non-operative management of fibroadenomas widely adopted, the importance of phyllodes tumours today lies in the need to differentiate them from other benign breast lesions.
  • All breast lumps should be triple assessed and the diagnosis of a phyllodes tumour considered in women, particularly over the age of 35 years, who present with a rapidly growing "benign" breast lump.
  • Treatment can be by either wide excision or mastectomy provided histologically clear specimen margins are ensured.
  • The role of chemotherapy, radiotherapy, and hormonal manipulation in both the adjuvant and palliative settings remain to be defined.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1988 Apr;58(4):301-5 [2855393.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1486-9 [2550124.001]
  • [Cites] Ann R Coll Surg Engl. 1989 Sep;71(5):285-8 [2552895.001]
  • [Cites] Surg Gynecol Obstet. 1990 Mar;170(3):193-6 [2154867.001]
  • [Cites] Br J Surg. 1966 May;53(5):450-5 [4378155.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):1320-3 [2156899.001]
  • [Cites] Am J Clin Pathol. 1990 Apr;93(4):480-5 [2157332.001]
  • [Cites] Eur J Surg Oncol. 1990 Jun;16(3):215-9 [2161352.001]
  • [Cites] Br J Clin Pract Suppl. 1989 Nov;68:147-9; discussion 157-8 [2562204.001]
  • [Cites] Zentralbl Chir. 1991;116(5):327-36 [1647600.001]
  • [Cites] Clin Radiol. 1991 Jul;44(1):8-12 [1651822.001]
  • [Cites] AJR Am J Roentgenol. 1991 Oct;157(4):715-9 [1654022.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):2017-22 [1655234.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):141-7 [1309302.001]
  • [Cites] Am Surg. 1994 Aug;60(8):583-5 [8030812.001]
  • [Cites] Pathol Res Pract. 1994 May;190(5):474-81 [7991467.001]
  • [Cites] Acta Cytol. 1994 Nov-Dec;38(6):891-7 [7992575.001]
  • [Cites] Am Surg. 1995 Apr;61(4):350-5 [7893104.001]
  • [Cites] Ann R Coll Surg Engl. 1995 May;77(3):181-4 [7598414.001]
  • [Cites] Breast Cancer Res Treat. 1998 Apr;48(3):205-10 [9598867.001]
  • [Cites] Ann Acad Med Singapore. 1998 Mar;27(2):200-3 [9663310.001]
  • [Cites] Diagn Cytopathol. 1999 Feb;20(2):53-6 [9951596.001]
  • [Cites] Eur Radiol. 1999;9(2):356-60 [10101663.001]
  • [Cites] Br J Surg. 1999 Mar;86(3):396-9 [10201787.001]
  • [Cites] Arch Surg. 1999 May;134(5):487-92; discussion 492-3 [10323420.001]
  • [Cites] Histopathology. 1999 Jun;34(6):491-6 [10383692.001]
  • [Cites] Eur J Surg Oncol. 1999 Aug;25(4):352-5 [10419703.001]
  • [Cites] Histopathology. 1999 Aug;35(2):162-9 [10460662.001]
  • [Cites] Aust N Z J Surg. 1999 Sep;69(9):635-8 [10515335.001]
  • [Cites] Cancer. 1951 Nov;4(6):1286-1332 [14886887.001]
  • [Cites] Cancer. 1954 Mar;7(2):335-53 [13141227.001]
  • [Cites] Br J Surg. 1961 Mar;48:519-21 [13685750.001]
  • [Cites] Ann Surg. 1950 Feb;131(2):243-51, illust [15402797.001]
  • [Cites] Cancer. 1965 Jun;18:697-710 [14297466.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4046-9 [1319837.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):203-7 [1311887.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):215-21 [1311889.001]
  • [Cites] Cancer. 1992 May 1;69(9):2271-5 [1314127.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):654-7 [1317204.001]
  • [Cites] Aust N Z J Surg. 1992 Aug;62(8):628-33 [1322660.001]
  • [Cites] Mod Pathol. 1992 May;5(3):232-9 [1323101.001]
  • [Cites] Cancer. 1992 Oct 15;70(8):2115-20 [1327488.001]
  • [Cites] Eur J Radiol. 1992 Jul-Aug;15(1):11-4 [1327792.001]
  • [Cites] Eur J Surg Oncol. 1992 Dec;18(6):545-9 [1335886.001]
  • [Cites] Eur J Surg Oncol. 1993 Feb;19(1):70-3 [8382173.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):376-9 [8383473.001]
  • [Cites] Cancer. 1993 May 15;71(10):3020-4 [8387873.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1252-6 [8393684.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4071-4 [8395336.001]
  • [Cites] Am J Surg. 1994 May;167(5):477-80 [8185030.001]
  • [Cites] J Surg Oncol. 1994 Jun;56(2):108-12 [8007675.001]
  • [Cites] Histopathology. 1995 Sep;27(3):205-18 [8522284.001]
  • [Cites] Radiology. 1996 Jan;198(1):121-4 [8539362.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 17;88(2):116-22 [8537972.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):910-6 [8608483.001]
  • [Cites] Surg Clin North Am. 1996 Apr;76(2):383-92 [8610270.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1779-85 [8625047.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jul;167(1):187-9 [8659370.001]
  • [Cites] J R Coll Surg Edinb. 1996 Aug;41(4):244-5 [8772074.001]
  • [Cites] Acta Cytol. 1997 Mar-Apr;41(2):321-6 [9100761.001]
  • [Cites] Cytopathology. 1997 Jun;8(3):177-87 [9202893.001]
  • [Cites] Am J Surg Pathol. 1998 Jan;22(1):64-9 [9422317.001]
  • [Cites] Johns Hopkins Med J. 1967 Jan;120(1):33-45 [4289572.001]
  • [Cites] Cancer. 1967 Dec;20(12):2090-9 [4294565.001]
  • [Cites] Oncology. 1968;22(2):145-58 [4301320.001]
  • [Cites] Ann Surg. 1970 Jun;171(6):849-56 [4316088.001]
  • [Cites] Can J Surg. 1971 Jan;14(1):31-7 [4322170.001]
  • [Cites] Ann Surg. 1971 Apr;173(4):520-8 [4324792.001]
  • [Cites] J Surg Oncol. 1972;4(2):131-47 [4338176.001]
  • [Cites] Br J Surg. 1974 Feb;61(2):113-7 [4361232.001]
  • [Cites] Am Surg. 1974 May;40(5):295-301 [4362487.001]
  • [Cites] Ann Surg. 1974 Nov;180(5):796-8 [4370747.001]
  • [Cites] Surg Gynecol Obstet. 1975 Jun;140(6):929-32 [165582.001]
  • [Cites] Cancer. 1976 Apr;37(4):1737-46 [177175.001]
  • [Cites] Arch Surg. 1976 May;111(5):611 [178291.001]
  • [Cites] Cancer. 1976 Sep;38(3):1402-6 [182356.001]
  • [Cites] Surg Gynecol Obstet. 1978 Mar;146(3):358-64 [204070.001]
  • [Cites] Cancer. 1978 May;41(5):1974-83 [206344.001]
  • [Cites] Am J Clin Pathol. 1978 Aug;70(2):211-6 [211844.001]
  • [Cites] Cancer. 1981 Apr 15;47(8):2016-21 [6261932.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1981;392(1):1-6 [6269275.001]
  • [Cites] Am Surg. 1982 Apr;48(4):157-66 [6282155.001]
  • [Cites] Am J Surg. 1982 Sep;144(3):341-3 [6287874.001]
  • [Cites] Cancer Detect Prev. 1982;5(2):211-9 [6290062.001]
  • [Cites] Radiol Clin North Am. 1983 Mar;21(1):27-50 [6300955.001]
  • [Cites] Am J Surg. 1983 Dec;146(6):712-4 [6316797.001]
  • [Cites] Arch Intern Med. 1985 Jun;145(6):1127-8 [2988474.001]
  • [Cites] Arch Gynecol. 1985;236(3):173-81 [2990358.001]
  • [Cites] Cancer. 1986 Nov 15;58(10):2282-9 [3019505.001]
  • [Cites] Am J Surg. 1987 Mar;153(3):276-80 [3030151.001]
  • [Cites] Clin Radiol. 1987 May;38(3):287 [3034476.001]
  • [Cites] Br J Surg. 1987 Sep;74(9):857-9 [3664257.001]
  • [Cites] Acta Cytol. 1988 Jan-Feb;32(1):63-6 [3336956.001]
  • [Cites] Acta Pathol Jpn. 1988 Jan;38(1):21-33 [2834912.001]
  • [Cites] Arch Pathol Lab Med. 1988 Jul;112(7):752-6 [2838007.001]
  • [Cites] Arch Surg. 1988 Sep;123(9):1079-83 [2843145.001]
  • [Cites] Surgery. 1989 Feb;105(2 Pt 1):141-7 [2536964.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2088-92 [2541882.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2532-6 [2541890.001]
  • (PMID = 11423590.001).
  • [ISSN] 0032-5473
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 111
  • [Other-IDs] NLM/ PMC1760996
  •  go-up   go-down


7. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Correspondingly, expression of GLI1, a transcription factor and transcriptional product of hedgehog signaling, was increased 8-fold in cancer epithelial cell lines; however, PTCH1, also a transcriptional target of hedgehog signaling in many cell types, was not increased.
  • GLI1 protein and mRNA, and PTCH1 and sonic hedgehog (SHH) proteins were elevated in 3 of 10 breast cancers; however, PTCH1 transcripts were not consistently increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • Treatment with sonic hedgehog ligand diminished the cyclopamine-induced reduction in GLI-dependent promoter activity in MCF10AT and MDA-MB-435 and viability of MDA-MB-435.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.
  • Determination as to whether the increase in GLI1 and SHH expression in breast cancer indicates a significant increase in hedgehog signaling will require further evaluation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


8. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcoma of the breast.
  • BACKGROUND AND OBJECTIVES: Primary sarcoma occurring in breast is rare and comprises 0.5-1% of all breast neoplasm.
  • PATIENTS AND METHODS: We carried out a retrospective analysis of 19 patients with primary sarcoma of the breast treated between 1982 and 2002.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Two patients received chemotherapy.
  • After a mean follow-up time of 34.5 months (median 25 months), eight patients failed.
  • Failure was local in five, opposite breast in one, and both local and distant in two.
  • CONCLUSIONS: Primary sarcomas of the breast are aggressive tumors.
  • Surgical treatment should consist of at least simple mastectomy.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Varras M, Akrivis Ch: Large endometrial polyp with sarcomatous stromal components following long-term tamoxifen treatment for breast cancer: a case report and review of the literature. Eur J Gynaecol Oncol; 2003;24(6):565-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large endometrial polyp with sarcomatous stromal components following long-term tamoxifen treatment for breast cancer: a case report and review of the literature.
  • Tamoxifen is commonly used in the management of patients with breast cancer because of its anti-oestrogenic effects to the breasts.
  • We describe a rare case of a large endometrial polyp with sarcomatous stromal components in a 73-year-old breast cancer patient treated daily with 20 mg of tamoxifen for four years.
  • The glands of the polyp were lined by benign appearing epithelium.
  • A postoperative computed tomography scan showed many focal hypodense lesions in the hepatic lobes with a well-defined profile suggestive of metastatic disease and the patient was referred for combined chemotherapy.
  • In conclusion, a case of a mesenchymal malignant neoplasm arising in the uterus of a breast cancer patient treated with tamoxifen is reported and its clinical, histological and immunohistochemical features are discussed.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrial Neoplasms / diagnosis. Mixed Tumor, Mullerian / diagnosis. Selective Estrogen Receptor Modulators / administration & dosage. Tamoxifen / administration & dosage
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Polyps / diagnosis. Polyps / pathology. Polyps / surgery. Survivors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658606.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 32
  •  go-up   go-down


10. D'Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, Carone MD, Abbolito MR, Carlini S, Perri P, Ricciotti A, Botti C, Conti F, Vici P, Chiappetta NR, Cognetti F, Buonomo O, Guadagni F: Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat; 2001 Jul;68(1):9-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
  • The efficacy of CEA and CA15-3 tumor markers in monitoring breast cancer was evaluated in 1365 patients with either benign (n = 534) or malignant (n = 831) breast diseases.
  • Thirty-nine breast cancer patients were monitored before and after neoadjuvant chemotherapy.
  • Three hundred forty-nine patients were monitored during post-surgical follow-up for either a minimum of 5 years or until time of recurrence.
  • Twenty-one patients with metastases were also monitored during chemotherapy.
  • Longitudinal monitoring of metastatic patients undergoing chemotherapy demonstrated that, when positive, both CA 15-3 and TPS paralleled response to treatment.
  • TPS monitoring may provide additional value when used in combination with CA15-3 during post-surgical follow-up of breast cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / diagnosis. Breast Neoplasms / mortality. Mucin-1 / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Peptides / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / blood. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / mortality. Carcinoma, Lobular / secondary. Carcinoma, Lobular / therapy. Case-Control Studies. Disease-Free Survival. Female. Fibrocystic Breast Disease / blood. Humans. Italy. Longitudinal Studies. Mastectomy. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Staging. Postoperative Period. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11678313.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Peptides; 0 / tissue polypeptide specific antigen
  •  go-up   go-down


11. Popescu I, Ciurea S, Romanescu D, Boros M: Isolated resection of the caudate lobe: indications, technique and results. Hepatogastroenterology; 2008 May-Jun;55(84):831-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: This paper reports a series of 24 isolated caudate lobe resections (ICLR), performed for 13 benign tumors (10 hemangiomas, 2 focal nodular hyperplasias, 1 adenoma) and 11 malignant tumors (3 hepatocarcinomas, 1 peripheral cholangiocarcinoma and 7 metastatic - 5 colorectal carcinomas, 1 breast carcinoma, 1 adrenal carcinoma).
  • From the 10 patients with malignant tumors who survived the operation, 7 developed recurrences: 2 intrahepatic, 1 retroperitoneal, 4 systemic.
  • Aggressive chemotherapy and follow-up are recommended.
  • [MeSH-minor] Adenoma, Liver Cell / mortality. Adenoma, Liver Cell / pathology. Adenoma, Liver Cell / surgery. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adult. Bile Duct Neoplasms / mortality. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / surgery. Breast Neoplasms / mortality. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Cholangiocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Female. Focal Nodular Hyperplasia / mortality. Focal Nodular Hyperplasia / pathology. Focal Nodular Hyperplasia / surgery. Hemangioma / mortality. Hemangioma / pathology. Hemangioma / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Complications / etiology. Postoperative Complications / mortality. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705277.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


13. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • There seems not to be any difference in the distribution of the percentage of CD133-1- and CD133-2-expressing cells according to clinicopathologic parameters and response to primary chemotherapy.
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


14. Pricop M, Ioanid N, Muscă S, Strat L, Slătineanu S: [Phyllodes tumor. The experience of the 4th Obstetrics-Gynecology Department]. Rev Med Chir Soc Med Nat Iasi; 2002 Jan-Mar;106(1):53-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumor. The experience of the 4th Obstetrics-Gynecology Department].
  • Between the 1st of January 1994 and the 1st of November 2001 587 operations have been performed as treatment of breast tumors in the IVth Obstetrics and Gynecology Department.
  • The phyllodes tumor has been diagnosed in 11 cases (1.8% of the benign breast masses).
  • The most common aspect is a round, hard, unpainful breast mass.
  • The surgical treatment is mandatory but radiotherapy, chemotherapy and endocrine treatment protocols have been brought up.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12635360.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


15. Zimny M, Siggelkow W: Positron emission tomography scanning in gynecologic and breast cancers. Curr Opin Obstet Gynecol; 2003 Feb;15(1):69-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positron emission tomography scanning in gynecologic and breast cancers.
  • PURPOSE OF REVIEW: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose represents a noninvasive functional imaging modality that is based on metabolic characteristics of malignant tumors.
  • The recent findings of this technique in breast cancer, cervical cancer, ovarian cancer, and other gynecologic malignancies are discussed.
  • RECENT FINDINGS: In breast cancer, positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose is more accurate than conventional methods for the staging of distant metastases, enables early assessment of treatment response in patients undergoing primary chemotherapy.
  • The diagnostic accuracy for axillary lymph node staging depends on the tumor load of the lymph nodes.
  • The sensitivity of this technique in detecting primary breast cancer is limited in small breast lesions and invasive lobular cancer.
  • False negative findings in well differentiated adenocarcinoma and borderline lesions as well as false positive findings in benign conditions limit the role of positron emission tomography scanning for the differential diagnosis of adnex tumors.
  • SUMMARY: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose reveals unique information about tumor metabolism in gynecologic malignancies and breast cancer.
  • This technique is complementary to morphological imaging for primary diagnosis, staging and re-staging.
  • It may become the method of choice for the early assessment of treatment response in breast cancer and the detection of recurrent disease in ovarian cancer.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Genital Neoplasms, Female / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Tomography, Emission-Computed / methods
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Predictive Value of Tests. Prognosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544505.001).
  • [ISSN] 1040-872X
  • [Journal-full-title] Current opinion in obstetrics & gynecology
  • [ISO-abbreviation] Curr. Opin. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 62
  •  go-up   go-down


16. Giordano SH, Buzdar AU, Hortobagyi GN: Breast cancer in men. Ann Intern Med; 2002 Oct 15;137(8):678-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer in men.
  • PURPOSE: Breast cancer in men is uncommon; 1500 new cases are diagnosed in the United States yearly.
  • Optimal management of breast cancer in men is unknown because the rarity of the disease precludes large randomized trials.
  • DATA SOURCES: Articles published between 1942 and 2000 on breast cancer in men were identified by using CancerLit, MEDLINE, and study bibliographies.
  • STUDY SELECTION: All retrospective series and studies focusing on the epidemiology, risk factors, genetics, and pathology of breast cancer in men.
  • DATA EXTRACTION: Data on the epidemiology, risk factors, genetics, pathology, molecular markers, prognostic factors, therapy, and outcomes of breast cancer in men.
  • DATA SYNTHESIS: Carcinoma of the male breast accounts for 0.8% of all breast cancers.
  • Risk factors include testicular disease, benign breast conditions, age, Jewish ancestry, family history, and the Klinefelter syndrome.
  • BRCA2 mutations predispose men to breast cancer and may account for 4% to 14% of all cases.
  • Prognostic factors include tumor size, histologic grade, and lymph node status; survival is similar to that of breast cancer in women when patients are matched for age and stage.
  • Adjuvant hormonal therapy and chemotherapy, using the same guidelines as for women, are recommended for men.
  • Hormonal therapy is the primary therapy for metastatic disease; chemotherapy should be reserved for hormone-refractory disease.
  • CONCLUSION: Breast cancer is similar in men and women; however, breast cancer in men is more frequently hormone receptor positive and may be more sensitive to hormonal therapy.
  • [MeSH-major] Breast Neoplasms, Male
  • [MeSH-minor] Biomarkers, Tumor. Genes, BRCA2. Humans. Male. Mutation. Neoplasm Metastasis. Prognosis. Risk Factors. United States / epidemiology


17. Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P: Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer; 2001 May 20;95(3):156-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness.
  • Telomerase activity was observed and correlated with aggressiveness in different neoplasms such as breast, prostate, blood and brain cancers, among others.
  • To investigate whether telomerase activity is an index of aggressiveness in bone and soft tissue lesions of the extremities, 66 biopsy samples from our tissue bank were studied.
  • These samples included 43 high-grade sarcomas, 9 aggressive benign tumors and 14 totally benign lesions.
  • Among benign lesions, only 2 aneurysmal bone cysts showed higher telomerase activity than the cut-off point, whereas all the other benign lesions had lower activity.
  • Our results indicate that high levels of telomerase activity in bone and soft tissue lesions correlate with more aggressive clinical behavior in patients treated with surgery alone.
  • An interesting inverse correlation between telomerase activity and occurrence of pulmonary metastasis was detected in osteosarcoma patients treated with chemotherapy.
  • A parallel increase of telomerase activity and malignancy was observed in the adipose and cartilagineous tissue lesions.
  • Our data suggest that telomerase activity could be considered a marker of tumor aggressiveness for bone and soft tissue lesions.
  • The results obtained in osteosarcoma samples suggest that low levels of telomerase activity may be predictive of the prognosis and should influence the therapeutic protocol.
  • [MeSH-major] Bone Neoplasms / enzymology. Soft Tissue Neoplasms / enzymology. Telomerase / metabolism
  • [MeSH-minor] Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11307148.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


18. De Vries J, Van der Steeg AF, Roukema JA: Trait anxiety determines depressive symptoms and fatigue in women with an abnormality in the breast. Br J Health Psychol; 2009 Feb;14(Pt 1):143-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trait anxiety determines depressive symptoms and fatigue in women with an abnormality in the breast.
  • OBJECTIVES: The aim was to examine the role of trait anxiety and diagnosis on depressive symptoms and fatigue in women with early stage breast cancer or benign breast problems.
  • METHODS: From the 169 participating women, 81 patients had breast cancer and 88 benign breast problems.
  • Questionnaires for depressive symptoms and fatigue were completed before diagnosis (T1) and 1 (T2), 3 (T3), and 6 (T4) months after diagnosis (benign patients) or surgical treatment (breast cancer patients).
  • A trait anxiety questionnaire was only completed before diagnosis was known.
  • RESULTS: Trait anxiety, assessed before diagnosis, was the only significant predictor of depressive symptoms at T4, even when depressive symptoms at baseline was included in the analysis.
  • Demographic characteristics, diagnosis (benign or breast cancer) and adjuvant treatment (chemotherapy, radiotherapy, hormone therapy) did not play a role.
  • Patients with breast cancer or benign breast problems scoring high on trait anxiety, scored higher on depressive symptoms and fatigue than the other patients, at all time points.
  • CONCLUSIONS: Trait anxiety plays a role in experiencing depressive symptoms and fatigue over time.
  • [MeSH-major] Anxiety Disorders / epidemiology. Anxiety Disorders / psychology. Breast Neoplasms / epidemiology. Breast Neoplasms / psychology. Depressive Disorder / epidemiology. Depressive Disorder / psychology. Fatigue / epidemiology. Fatigue / psychology
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Neoplasm Staging. Prospective Studies. Severity of Illness Index. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544184.001).
  • [ISSN] 1359-107X
  • [Journal-full-title] British journal of health psychology
  • [ISO-abbreviation] Br J Health Psychol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jürchott K, Schmitt M, Royer HD: Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer; 2002 Jan 20;97(3):278-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
  • Intrinsic or acquired resistance to chemotherapy is responsible for failure of current treatment regimens in breast cancer patients.
  • The Y-box protein YB-1 regulates expression of the P-glycoprotein gene mdr1, which plays a major role in the development of a multidrug-resistant tumor phenotype.
  • In human breast cancer, overexpression and nuclear localization of YB-1 is associated with upregulation of P-glycoprotein.
  • In our pilot study, we analyzed the clinical relevance of YB-1 expression in breast cancer (n = 83) after a median follow-up of 61 months and compared it with tumor-biologic factors already used for clinical risk-group discrimination, i.e., HER2, urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1).
  • High YB-1 expression in tumor tissue and surrounding benign breast epithelial cells was significantly associated with poor patient outcome.
  • In patients who received postoperative chemotherapy, the 5-year relapse rate was 66% in patients with high YB-1 expression.
  • YB-1 expression thus indicates clinical drug resistance in breast cancer.
  • Moreover, YB-1 correlates with breast cancer aggressiveness: in patients not treated with postoperative chemotherapy, those with low YB-1 expression are still free of disease, whereas the 5-year relapse rate in those with high YB-1 was 30%.
  • In conclusion, YB-1 demonstrated prognostic and predictive significance in breast cancer by identifying high-risk patients in both the presence and absence of postoperative chemotherapy, independent of tumor-biologic factors currently available for clinical decision making.
  • [MeSH-major] Breast Neoplasms / metabolism. CCAAT-Enhancer-Binding Proteins / metabolism. CCAAT-Enhancer-Binding Proteins / physiology. DNA-Binding Proteins. Drug Resistance, Neoplasm. Plasminogen Activator Inhibitor 1 / metabolism. Receptor, ErbB-2 / metabolism. Transcription Factors. Urokinase-Type Plasminogen Activator / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / metabolism. Cell Division. Disease-Free Survival. Drug Resistance, Multiple. Female. Humans. Immunohistochemistry. Menopause. Middle Aged. NFI Transcription Factors. Neoplasm Metastasis. Nuclear Proteins. Phenotype. Postmenopause. Premenopause. Time Factors. Y-Box-Binding Protein 1

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11774277.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / DNA-Binding Proteins; 0 / NFI Transcription Factors; 0 / Nuclear Proteins; 0 / Plasminogen Activator Inhibitor 1; 0 / Transcription Factors; 0 / Y-Box-Binding Protein 1; 0 / YBX1 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


20. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Histological sub-type, type of surgery (definitive or not) and stromal proliferation determine the prognosis.
  • Surgery (often radical) is the standard treatment.
  • Radiotherapy is recommended in case of high-grade tumor and after conservativetreatment.
  • Breast sarcomas are even rarer.
  • All histological types exist with a predominance of histiofibrocytome type tumors.
  • Grade, involved margins and sometimes tumor necrosis are major prognostics factors.
  • Among the various sub-types, angiosarcoma is characterized by a high risk of occurrence in irradiated fields and by a poor prognosis with a high risk of lung metastases.
  • The treatment is mostly based on mastectomy without lymph node dissection given the exceptional flooding axillary.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • Systemic chemotherapy is not a standard but should be discussed in the forms at high risk of relapse (like angiosarcoma).
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


21. Seeger H, Wallwiener D, Mueck AO: Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol; 2008 Oct;24(10):576-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis.
  • BACKGROUND: Epidemiological data suggest an enhanced breast cancer risk during estrogen/progestogen therapy as compared to estrogen monotherapy in postmenopausal women.
  • Estrogens are known to be mitogenic agents for benign and cancerous breast epithelial cells whereas the role of progestogens is unclear.
  • Tumor-associated macrophages play a crucial role in tumor growth and metastasis due to the synthesis of various cytokines such as tumor necrosis factor-alpha (TNF-alpha), which can stimulate the synthesis of proliferative and angiogenic factors in tumor cells.
  • METHODS: MCF-7 cells, a human estrogen- and progesterone-receptor-positive human breast cancer cell line, were used for the experiments.
  • In combinations with E(2), the E(2)-induced increase of MCP-1 was reduced by NET and MPA and the increase of VEGF was diminished by P and NET, but not by MPA.
  • The E(2)-induced decrease of MMP-9 was not antagonized by P and NET, but completely abolished by MPA.
  • CONCLUSION: Our results indicate that E(2) may have a stimulating effect on pre-existing tumor growth and metastasis.
  • Thus the choice of progestogen addition to estrogen therapy may be important, especially since different effects can occur in the case of pre-existing tumor cells.
  • [MeSH-major] Biomarkers / metabolism. Breast Neoplasms / pathology. Cell Proliferation. Estradiol / pharmacology. Progestins / pharmacology. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Chemokine CCL2 / analysis. Chemokine CCL2 / metabolism. Dose-Response Relationship, Drug. Female. Humans. Matrix Metalloproteinase 9 / metabolism. Medroxyprogesterone Acetate / pharmacology. Neoplasm Metastasis. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012101.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Progestins; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 4TI98Z838E / Estradiol; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


22. Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS: Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. Am J Obstet Gynecol; 2000 Jul;183(1):18-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Among women the association between heat shock protein immunity and cancer has been examined primarily for breast cancer.
  • Autoantibodies to the 27-kd heat shock protein were detected in some patients with breast cancer but not in control subjects, and the presence of these antibodies was correlated with improved survival.
  • We examined the relationship between autoimmunity to heat shock proteins and the diagnosis of malignancies of the female genital tract.
  • STUDY DESIGN: Serum samples from women seen for possible gynecologic malignancies or returning for evaluation after surgery, radiation, chemotherapy, or a combination for gynecologic cancers were tested for immunoglobulin G antibodies to the 27-kd, 60-kd, 70-kd, and 90-kd heat shock proteins by enzyme-linked immunosorbent assay with the purified recombinant proteins bound to wells of a microtiter plate.
  • RESULTS: Antibodies to the 27-kd heat shock protein were detected in only 1 of 29 healthy control subjects (3.4%) and 1 of 23 women whose lesions were benign (4.3%).
  • In marked contrast, 39 of 96 women with gynecologic cancers (40.6%) had positive antibody detection (P =.0004 vs benign).
  • Similar prevalences of antibodies to the 27-kd heat shock protein were seen among patients with cancer who had untreated active disease and after treatment.
  • [MeSH-major] Autoantibodies / blood. Genital Neoplasms, Female / immunology. Heat-Shock Proteins. Neoplasm Proteins / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10920302.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


23. Galiè M, Farace P, Merigo F, Fiorini S, Tambalo S, Nicolato E, Sbarbati A, Marzola P: Washout of small molecular contrast agent in carcinoma-derived experimental tumors. Microvasc Res; 2009 Dec;78(3):370-8
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of contrast-enhanced magnetic resonance imaging (MRI) for the assessment of breast carcinomas reveals satisfactory sensitivity, but due to low specificity, it does not obviate the need for subsequent tissue sampling.
  • Its capability to differentiate benign from malignant lesion is under continuous investigation.
  • In particular, the study of the washout pattern is considered a promising tool to improve in vivo diagnosis and even to evaluate the response under chemotherapy.
  • To provide a comprehensive characterization of this parameter in malignant tumor models, in vivo mapping of the washout of small molecular contrast agent (Gd-DTPA, molecular weight 0.57 kDa) was carried out in three transplanted/spontaneous mammary tumors, which differed in their histopathological and microvascular features.
  • It resulted that in all models around 40% of tumor volume lacks efficient washout; washout areas are frequently, but not always, restricted to the tumor periphery and that non-washout areas are not restricted to necrotic regions.
  • [MeSH-major] Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Mammary Neoplasms, Experimental / diagnosis
  • [MeSH-minor] Animals. Female. Lymphatic Vessels / pathology. Mice. Mice, Inbred Strains. Microvessels / pathology. Neoplasm Transplantation. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19804787.001).
  • [ISSN] 1095-9319
  • [Journal-full-title] Microvascular research
  • [ISO-abbreviation] Microvasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


24. Wang L, Wang Y, Liu Y, Cheng M, Wu X, Wei H: Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. J Exp Clin Cancer Res; 2009;28:57
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection.
  • BACKGROUND: Immunocytochemistry and RT-PCR have been widely used for the detection of circulating tumor cells in patients with breast cancer but their specificity is limited.
  • Our purpose is to utilize a convenient and specific technology to detect circulating tumor cells in breast cancer patients.
  • A total of 73 blood specimens including 25 healthy volunteers and 48 patients with breast carcinoma and benign tumor were tested by flow cytometry to quantify the expression of CK19.
  • CK19 was detected in 27% of breast cancer patients but none control gives positive result.
  • Fifteen patients were observed during three month chemotherapy after surgery, and most of their CK19 expression levels declined after treatment.
  • CONCLUSION: Our research convinces that the detection of CK19 in peripheral blood by flow cytometry is also a specific and feasible method to monitor circulating tumor cells in breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Flow Cytometry / methods. Keratin-19 / metabolism. Neoplastic Cells, Circulating / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Humans. Indicator Dilution Techniques. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):65-73 [11121864.001]
  • [Cites] J Cancer Res Ther. 2005 Oct-Dec;1(4):221-6 [17998657.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):17-20 [11438448.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3404-12 [12177100.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1111-7 [12370762.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4338-43 [12409333.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):849-55 [12796021.001]
  • [Cites] Jpn J Clin Oncol. 2003 Apr;33(4):167-72 [12810830.001]
  • [Cites] Breast. 2004 Feb;13(1):35-41 [14759714.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1392-400 [14977842.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):903-11 [15333648.001]
  • [Cites] Acta Biochim Pol. 2004;51(3):747-55 [15448736.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1194-8 [9820179.001]
  • [Cites] Breast Cancer Res Treat. 2004 Oct;87(3):215-24 [15528964.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1813-20 [15505629.001]
  • [Cites] Int J Oncol. 2005 Mar;26(3):721-30 [15703829.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1420-30 [15735118.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):251-6 [15937912.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):355-60 [16203027.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2013-9 [16287086.001]
  • [Cites] Biomed Pharmacother. 2005 Oct;59 Suppl 2:S384-6 [16507415.001]
  • [Cites] Arch Oral Biol. 2006 Dec;51(12):1112-9 [16806049.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R36 [16846533.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3A):1337-41 [17593628.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1623-31 [17515404.001]
  • [Cites] Ann Oncol. 2001 Jan;12(1):39-46 [11249047.001]
  • (PMID = 19397830.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Keratin-19
  • [Other-IDs] NLM/ PMC2685124
  •  go-up   go-down


25. Fang Z, Matsumoto S, Ae K, Kawaguchi N, Yoshikawa H, Ueda T, Ishii T, Araki N, Kito M: Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan. J Orthop Sci; 2004;9(3):242-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan.
  • Radiation therapy (RT) is commonly used to treat malignant tumors, but it leads to side effects and complications.
  • This article focuses on the clinical manifestations, pathological characteristics, and therapeutic effects concerning postradiation soft tissue sarcomas (PRSTSs).
  • Their histological types were malignant fibrous histiocytoma (eight cases), extraskeletal osteosarcoma (four cases), fibrosarcoma (one case), and leiomyosarcoma (one case).
  • The primary diagnoses, RT history, latent period, and outcome of treatment were studied retrospectively.
  • The original tumors included uterine cancer (seven cases), breast cancer (four cases), synovial sarcoma (one case), squamous cell carcinoma (one case), and Hodgkin's disease (one case).
  • There were 13 women and 1 man, with ages ranging from 23 to 77 years (mean 58 years) at the time of the appearance of the PRSTS.
  • RT doses ranged from 48 to 91 Gy (mean 62 Gy).
  • One of three who underwent RT and one of five who underwent chemotherapy (CT) responded.
  • The prognosis of the PRSTS patients was not poor if the tumor could be removed with a wide surgical margin.
  • Because adjuvant therapies including RT and CT had a poor effect on PRSTSs, the primary treatment of PRSTSs should be radical resection with a wide margin.
  • [MeSH-major] Neoplasms, Second Primary / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / radiotherapy. Female. Histiocytoma, Benign Fibrous / etiology. Histiocytoma, Benign Fibrous / surgery. Humans. Japan. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Uterine Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] The Japanese Orthopaedic Association
  • (PMID = 15168177.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down


26. Yousef GM, Fracchioli S, Scorilas A, Borgoño CA, Iskander L, Puopolo M, Massobrio M, Diamandis EP, Katsaros D: Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer. Am J Clin Pathol; 2003 Mar;119(3):346-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study KLK14 gene expression in endocrine-related cancers, we studied its hormonal regulation in breast and ovarian cancer cell lines.
  • We then studied the expression of KLK14 by quantitative reverse transcriptase-polymerase chain reaction in 155 consecutive ovarian tumors and correlated these findings with clinicopathologic parameters, response to chemotherapy, and survival.
  • A stepwise reduction was observed in the levels of KLK14 messenger RNA in normal, benign, and cancerous tissues (P < .001).
  • Expression levels were significantly higher in patients with early stage disease and optimal debulking and in patients who responded to chemotherapy.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma / genetics. Gene Expression Regulation, Neoplastic. Kallikreins / genetics. Ovarian Neoplasms / genetics. Steroids / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Disease-Free Survival. Female. Humans. Middle Aged. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Receptors, Androgen / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured / drug effects. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12645335.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptors, Androgen; 0 / Steroids; EC 3.4.21.- / KLK14 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


27. Griffa B, Basilico V, Clerici D, Bellotti R, Scognamiglio G, Zanardo M, Capriata G: [Angiosarcoma of the breast after conservative surgery and radiotherapy for early breast carcinoma. Description of a case]. Minerva Chir; 2000 Nov;55(11):799-802
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiosarcoma of the breast after conservative surgery and radiotherapy for early breast carcinoma. Description of a case].
  • [Transliterated title] L'angiosarcoma della mammella dopo chirurgia conservativa e radioterapia per carcinoma mammario precoce. Descrizione di un caso clinico.
  • The occurrence of an angiosarcoma of the residual breast after conservative surgery and adjuvant radiotherapy for early mammary carcinoma is a very rare event.
  • Radiotherapy seems to be the most important etiological factor in the development of the neoplasm.
  • Diagnosis is often delayed, owing to the "benign" aspect of the lesion.
  • The only effective treatment is residual mastectomy, because chemotherapy is ineffective.
  • The case of a patient with a multicentric secondary angiosarcoma of the breast recently operated on is described.
  • [MeSH-major] Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Carcinoma, Ductal, Breast / radiotherapy. Hemangiosarcoma / pathology. Neoplasms, Radiation-Induced / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11265154.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


28. Simmons C, Amir E, Dranitsaris G, Clemons M, Wong B, Veith R, Cole DE: Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer. Anticancer Res; 2009 Jul;29(7):2707-11
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer.
  • BACKGROUND: Bisphosphonates (BPs) are considered the standard of care in metastatic breast cancer (MBC) patients with bone metastases.
  • MATERIALS AND METHODS: An exploratory analysis of serum calcium, parathyroid (PTH), and 25 hydroxycholecalsiferol (25-(OH)D) levels and their inter-relationships was undertaken in 46 MBC patients who had been on prolonged BP therapy.
  • CONCLUSION: In MBC patients with prolonged BP use, there appears to be a state of hyperparathyroidism similar to that seen with BP use in benign bone disease.
  • [MeSH-major] Breast Neoplasms / metabolism. Calcium / metabolism. Diphosphonates / therapeutic use. Neoplasm Metastasis / drug therapy


29. Korula A, Varghese J, Thomas M, Vyas F, Korula A: Malignant phyllodes tumour with intraductal and invasive carcinoma and lymph node metastasis. Singapore Med J; 2008 Nov;49(11):e318-21
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phyllodes tumours constitute 2-3 percent of fibroepithelial breast tumours, with a 1-2 percent rate of malignancy.
  • Carcinoma in a phyllodes tumour is distinctly uncommon, but has been known to occur in benign phyllodes tumours.
  • We describe a 51-year-old woman with a malignant phyllodes tumour with foci of intraductal carcinoma within the tumour and adjacent breast tissue.
  • Though the carcinoma was found to be invasive based on the presence of carcinomatous lymph node metastasis, extensive sampling did not yield an invasive component within the breast, probably because of the marked stromal overgrowth of the phyllodes.
  • Chemotherapy and irradiation were included in the postoperative management.
  • There is little consensus on the treatment and prognosis in these cases, and it is recommended that treatment be tailored to individual patients, based on the presence of invasion, lymph node metastasis and/or distant metastasis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma / diagnosis. Carcinoma / pathology. Phyllodes Tumor / diagnosis. Phyllodes Tumor / pathology
  • [MeSH-minor] Breast / pathology. Breast / surgery. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19037540.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


30. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM: Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology; 2008 Jul;248(1):79-87
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
  • PURPOSE: To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with breast cancer who underwent preoperative magnetic resonance (MR) imaging.
  • From 1995 to 2002, gadolinium-enhanced MR imaging data were acquired with a three time point high-resolution method in women undergoing neoadjuvant therapy for invasive breast cancers.
  • RESULTS: Breast tumor volume calculated from the number of voxels with SER values above a threshold corresponding to the upper limit of mean redistribution rate constant in benign tumors (0.88 minutes(-1)) and the volume of cancerous breast tissue infiltrating into the parenchyma were important predictors of disease recurrence.
  • Thirty percent of patients with recurrence and 67% of deceased patients were identified as having high risk before chemotherapy.
  • All three prechemotherapy parameters (total tumor volume, tumor volumes with high and low SER) and the postchemotherapy tumor volume with high SER were significantly different between the two groups.
  • The multivariate Cox proportional hazards regression showed that, of the three prechemotherapy covariates, only the low SER and high SER tumor volumes (P = .017 and .049, respectively) were significant and independent predictors of tumor recurrence.
  • Tumor volume with high SER was the only significant postchemotherapy covariate predictor (P = .038).
  • [MeSH-major] Breast Neoplasms / diagnosis. Image Enhancement / methods. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • [Cites] Med Phys. 1987 Jan-Feb;14(1):1-37 [3031439.001]
  • [Cites] J Magn Reson Imaging. 1997 Jan-Feb;7(1):91-101 [9039598.001]
  • [Cites] Radiology. 2005 Sep;236(3):789-800 [16118161.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):260-6 [10508285.001]
  • [Cites] Radiology. 1999 Apr;211(1):101-10 [10189459.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1774-81 [15908529.001]
  • [Cites] Breast J. 1999 Jan;5(1):13-21 [11348250.001]
  • [Cites] Crit Rev Diagn Imaging. 1995;36(4):287-338 [8845065.001]
  • [Cites] Clin Radiol. 1997 Jul;52(7):516-26 [9240704.001]
  • [Cites] J Magn Reson Imaging. 2003 Oct;18(4):467-77 [14508784.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2001 May;9(2):321-32, vi [11493422.001]
  • [Cites] Magn Reson Med. 1995 Apr;33(4):564-8 [7776889.001]
  • [Cites] J Magn Reson Imaging. 1999 Sep;10(3):223-32 [10508281.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):373-8 [12846686.001]
  • [Cites] Radiology. 2006 May;239(2):361-74 [16543585.001]
  • [Cites] Cancer. 1996 May 1;77(9):1844-9 [8646683.001]
  • [Cites] Br J Radiol. 1998 May;71(845):501-9 [9691895.001]
  • [Cites] Breast Cancer Res Treat. 1997 Aug;45(1):39-46 [9285115.001]
  • [Cites] Magn Reson Med. 2007 Sep;58(3):572-81 [17685424.001]
  • [Cites] J Magn Reson Imaging. 2000 Dec;12(6):965-74 [11105038.001]
  • [Cites] Radiology. 1995 Oct;197(1):33-8 [7568850.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):708-18 [15971199.001]
  • [Cites] Acta Radiol. 1998 May;39(3):279-84 [9571944.001]
  • [Cites] Eur J Radiol. 2005 Feb;53(2):199-205 [15664283.001]
  • [Cites] Radiology. 1997 Dec;205(3):837-42 [9393545.001]
  • [Cites] J Magn Reson Imaging. 1999 Dec;10(6):945-9 [10581507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):910-2 [11183740.001]
  • [Cites] J Comput Assist Tomogr. 2002 May-Jun;26(3):376-86 [12016367.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):615-21 [10433296.001]
  • [Cites] Br J Radiol. 1997 May;70(833):446-51 [9227224.001]
  • [Cites] Eur Radiol. 2001;11(9):1645-50 [11511885.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):511-9 [16161072.001]
  • [Cites] Magn Reson Imaging. 2004 May;22(4):475-81 [15120166.001]
  • (PMID = 18566170.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069587; United States / NCI NIH HHS / CA / R01 CA116182
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Azab SS, Salama SA, Hassan MH, Khalifa AE, El-Demerdash E, Fouad H, Al-Hendy A, Abdel-Naim AB: 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft. Cancer Chemother Pharmacol; 2008 Oct;62(5):893-902
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft.
  • PURPOSE: 2-Methoxyestradiol (2ME), an endogenous estradiol metabolite, was developed as a novel agent based on its antitumor activity and lack of toxicity.
  • This study was designed to investigate the modulatory effect of 2ME on the antitumor effect of doxorubicin (Dox) in resistant breast tumor xenograft.
  • Resistant MCF-7/Dox cells were implanted subcutaneously in nude mice METHODS: Treatment with Dox 5 mg/kg, 2ME 30 mg/kg and their combination continued twice a week for 2 weeks.
  • RESULTS: Following 28 days from starting the treatment with Dox alone, the change in tumor volume from first day of treatment was 455.6 +/- 16.2%.
  • Combined Dox and 2ME treatment significantly reduced tumor volume to 20.8 +/- 43%.
  • Also, combined therapy resulted in enhanced tumor apoptotic and reduced proliferative activities relative to Dox alone.
  • Examining body weight, hepatic and cardiac histopathology of the different treatment groups revealed no significant signs of toxicity.
  • CONCLUSION: These findings suggest that 2ME reverses Dox resistance, with benign side effects profile.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Breast Neoplasms / drug therapy. Doxorubicin / pharmacology. Drug Resistance, Neoplasm / drug effects. Estradiol / analogs & derivatives
  • [MeSH-minor] Algorithms. Angiogenesis Inhibitors / pharmacology. Animals. Apoptosis / drug effects. Body Weight / drug effects. Cell Proliferation / drug effects. Drug Synergism. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Liver / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Myocardium / pathology. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18253735.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibiotics, Antineoplastic; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol; 80168379AG / Doxorubicin
  •  go-up   go-down


32. Fajdić J, Gotovac N, Hrgović Z, Kristek J, Horvat V, Kaufmann M: Phyllodes tumors of the breast diagnostic and therapeutic dilemmas. Onkologie; 2007 Mar;30(3):113-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.
  • BACKGROUND: This article compares experiences in the diagnosis and treatment of phyllodes tumors from 2 regional institutions with the relevant literature.
  • PATIENTS AND METHODS: From 1991 to 2005, 2,848 breast cancer patients were treated in our institutions, 36 (1.44%) for phyllodes tumors.
  • The average tumor size was 5.1 cm (range 1.4-19.6).
  • Wide excision with tumor-free margins was carried out in 29 (80.5%) cases and mastectomy in 7 (19.4%) cases.
  • RESULTS: Histology showed the phyllodes tumors to be benign in 27 (75.0%), malignant in 6 (16.6%), and borderline in 3 (8.3%) cases.
  • In this period, recurrences of 3 (8.3%) malignant and 2 (5.6%) benign phyllodes tumors were diagnosed and treated.
  • The steroid receptor status was of no prognostic value in our patients, and chemotherapy was used in only 1 (2.7%) patient.
  • CONCLUSION: Our study shows that tumor size, margin infiltration, mitotic activity and degree of cellular atypia are important prognostic factors.
  • Although wide local excision is usually the treatment of choice, tumor recurrence is common.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / pathology. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Mitotic Index. Necrosis. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341897.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


33. Fleming NA, Hopkins L, de Nanassy J, Senterman M, Black AY: Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol; 2009 Aug;22(4):e45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Müllerian adenosarcoma is a rare neoplasm usually found in postmenopausal women.
  • It is a biphasic tumor, composed of a benign epithelial component and a malignant stromal component.
  • To date, this neoplasm has been reported in only 16 adolescent girls.
  • On physical examination, her vital signs were stable, and pubertal development was Tanner III breast and Tanner II pubic development.
  • Pathology confirmed a diagnosis of müllerian adenosarcoma originating from the endocervix.
  • After a thorough evaluation of the available literature, review with the Regional Tumor Board and extensive discussions with the family, a decision was made to perform a radical hysterectomy, bilateral salpingectomy, bilateral pelvic lymph node dissection, upper vaginectomy and preservation of ovaries.
  • The procedure was uncomplicated.
  • CONCLUSION: Müllerian adenosarcoma of the endocervix is a very rare pediatric tumor.
  • Due to the rarity of this tumor in this age group, optimal therapy is uncertain.
  • Chemotherapy and radiation have not been used in the absence of extensive pelvic and/or residual disease.
  • If recurrence occurs, it tends to be local and following prior conservative treatments such as cone biopsy or trachelectomy.


34. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, D'Alessandro R, Carone MD, Cicchetti A, Ricciotti A, Venturo I, Perri P, Di Filippo F, Cognetti F, Botti C, Roselli M: A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res; 2001 Aug;7(8):2357-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
  • PURPOSE: Carcinoembryonic antigen (CEA) is still a widely used test for monitoring breast cancer, although recent reports discourage its routine use because of low sensitivity.
  • This is a prospective study evaluating the efficacy of CEA and CA 15.3 in monitoring breast cancer.
  • EXPERIMENTAL DESIGN: Serum CEA and CA 15.3 were measured in 2191 patients with either benign (n = 738) or malignant (n = 1453) breast diseases.
  • Five hundred and forty-nine patients were monitored during postsurgical follow-up for either a minimum of 5 years or until time of recurrence.
  • Fifty-three patients with metastases were also monitored during chemotherapy.
  • Longitudinal monitoring of 53 metastatic patients undergoing chemotherapy demonstrated that, when positive, both CEA and CA 15.3 paralleled response to treatment, although CA 15.3 was a significantly more powerful marker for determining response to treatment.
  • CONCLUSIONS: CEA monitoring should be considered an expensive and inefficient method of follow-up evaluation for breast cancer patients, and it provides no additional value when used in combination with CA 15.3.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoembryonic Antigen / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / economics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Longitudinal Studies. Middle Aged. Mucin-1 / blood. Neoplasm Staging. Predictive Value of Tests. Prospective Studies. Radioimmunoassay / economics. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11489813.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1
  •  go-up   go-down


35. Pellegrino M, Vadrucci S, Tinelli A: [Angiomyofibroblastoma of the vulva: a rare but distinct entity. Case report and literature review]. Pathologica; 2007 Dec;99(6):438-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Angiomiofibroblastoma vulvare. Relazione su un caso, con revisione della letteratura. Una rara ma distinta entità.
  • Angiomyofibroblastoma is a benign vulvar tumour involving soft tissue that is characterized by alternating hypocellular and hypercellular areas of spindle stromal cells, admixed and aggregated around blood vessels.
  • It is important to recognize this entity as it shows benign behaviour with respect to other mesenchymal tumours of the vagina, which have a more aggressive behaviour.
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / surgery. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416337.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Number-of-references] 7
  •  go-up   go-down


36. Giordano G, Lombardi M, Brigati F, Mancini C, Silini EM: Clinicopathologic features of 2 new cases of uterine tumors resembling ovarian sex cord tumors. Int J Gynecol Pathol; 2010 Sep;29(5):459-67
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Generally, this entity is characterized by benign behavior.
  • In these examples, the pathologic diagnosis of UTROSCT was made incidentally after the clinical diagnosis of a leiomyoma and endometrial polyp.
  • On examination of small biopsies, the diagnosis was facilitated by specific immunohistochemical analysis using markers for the sex cord component.
  • In the other case, the neoplasm seemed to be the consequence of tamoxifen treatment for breast carcinoma.
  • After diagnosis, in this second case, the woman underwent hysterectomy that showed a residue of the tumor and cervical metastasis from the earlier breast carcinoma.
  • The differential diagnosis of UTROSCT and the role of immunohistochemistry in confirming a diagnosis are discussed.
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Lobular / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasms, Second Primary / pathology. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736772.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


37. Morikawa M, Demura Y, Mizuno S, Ameshima S, Ishizaki T, Okazawa H: FDG positron emission tomography imaging of drug-induced pneumonitis. Ann Nucl Med; 2008 May;22(4):335-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG positron emission tomography imaging of drug-induced pneumonitis.
  • Several studies have reported the findings of fluorine-18-labeled fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) in benign lung disease with diffuse pulmonary injury; however, the characteristics and effectiveness of FDG-PET imaging for interstitial pneumonitis have not been substantiated.
  • We report two cases of drug-induced pneumonitis in two patients treated for breast cancer who were diagnosed by FDG-PET examination.
  • Both the cases showed diffuse interstitial infiltration in the bilateral lungs on computed tomography, but the degree of FDG accumulation was different.
  • It is probable that the degree of FDG accumulation reflected the activity of the drug-induced pneumonitis.
  • [MeSH-minor] Aged. Anxiety Disorders / drug therapy. Anxiety Disorders / etiology. Brain Neoplasms / complications. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Dibenzothiazepines / adverse effects. Dibenzothiazepines / therapeutic use. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / adverse effects. Paclitaxel / therapeutic use. Positron-Emission Tomography. Quetiapine Fumarate. Sensitivity and Specificity. Tomography, X-Ray Computed. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535887.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dibenzothiazepines; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 2S3PL1B6UJ / Quetiapine Fumarate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement